Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C3BS CQR 1

Next Previous
Drug Profile

C3BS CQR 1

Alternative Names: Autologous cardiac progenitor stem cell therapy - Celyad Oncology; Bone marrow derived mesenchymal cardiopoietic cells - Celyad Oncology; C-Cure; C3BR-CQR-1; C3BS-CQR-1; Congestive heart failure cardiopoietic regenerative therapy - Celyad Oncology

Latest Information Update: 15 Jun 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardio3 BioSciences
  • Developer Celyad Oncology
  • Class Heart failure therapies; Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Chronic heart failure

Most Recent Events

  • 10 Jun 2020 Celyad is now called Celyad Oncology
  • 17 May 2018 Phase-III clinical trials in Chronic heart failure in USA (Intracoronary)
  • 01 Sep 2017 C3BS CQR 1 is still at phase III development stage for Chronic heart failure in European Union, Switzerland, Israel and Serbia (Intracoronary)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top